iTeos Therapeutics stock centers on pipeline risk and a 2.05 score
Published on 09/30/2026 at 09:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
iTeos Therapeutics stock centers on pipeline execution after its Altman Z-Score reached 2.05 on September 23, 2026. Eulerpool shows the score down 16.30 percent from 2.45 in 2025, putting financial resilience alongside clinical progress at the center of the stock story.
Pipeline remains the core asset
iTeos is a clinical-stage biopharmaceutical company focused on immuno-oncology therapies. Its pipeline includes inupadenant, an adenosine A2AR antagonist in Phase 2, and EOS-448, a TIGIT antagonist in Phase 1/2 development.
The company was established in 2011 and has 173 full-time employees. That compact operating base matches a business model built around advancing drug candidates through clinical development rather than reporting commercial product revenue.
Growth score stays measured
Invetso assigned iTeos a growth potential score of 5.1/10 in its September 1, 2026 update. The assessment describes revenue scaling as unproven and points to pipeline conversion as the main route to longer-term expansion.
For investors, the contrast is clear: the company has two named clinical programs, while its valuation case still depends on future trial outcomes and capital allocation. The 16.30 percent year-over-year decline in the Altman Z-Score adds a measurable risk marker to that development profile.
Nasdaq listing and biotech profile
iTeos trades under the ticker ITOS on Nasdaq, according to HBM Healthcare Investments. The company belongs to the biotechnology industry within the healthcare sector, and its investment case remains tied to clinical milestones rather than established product sales.
iTeos Therapeutics at a glance
- Company: iTeos Therapeutics, Inc.
- Ticker: ITOS
- Primary exchange: Nasdaq
- Sector / Industry: Healthcare / Biotechnology
- Altman Z-Score: 2.05 as of September 23, 2026
- Growth potential score: 5.1/10 as of September 1, 2026
